Endologix AFX2 Graft Risk Information Updated in FDA-Approved Labeling
The FDA is requiring new label warnings and post-marketing studies on the Endologix AFX2 graft system, which has been linked to potentially life-threatening endoleaks.
The FDA is requiring new label warnings and post-marketing studies on the Endologix AFX2 graft system, which has been linked to potentially life-threatening endoleaks.
The FDA is warning of potentially deadly endoleaks linked to endovascular graft systems, and call for patients with such systems to be closely monitored.
The FDA is warning of potential leaks in endovascular graft systems that could cause complications following aortic aneurysm repair surgery.